News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Terminates Marketing Agreement on the Non-Ionic Contrast Medium OPTIRAY

December 8, 2003

Tokyo, Japan - December 8, 2003 -Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) agreed with Tyco Healthcare Japan Co., Ltd. (president: Junrokuro Abe) to terminate the marketing agreement between the two companies regarding the non-ionic contrast medium Optiray (ioversol) following its expiration on March 31, 2004. At present, the Optiray series of products are sold to wholesalers through Yamanouchi. After April 1, 2004, all marketing and detailing activities will be conducted by Tyco Healthcare Japan.

Following termination of the agreement, Yamanouchi will transfer the marketing of the products listed below to Tyco Healthcare Japan. In the fiscal year ended in March 2003, Yamanouchi posted sales of about 10.5 billion yen with these products.

Optiray 160,240,320 and 350
Optiray 240 Syringe and 320 Syringe